Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Valvular Diseases Clear all
Active, not recruiting Not applicable Interventional

J-Valve TF Early Feasibility Study

NCT06034028
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
Interventions
J-Valve TF System
Device
Lead sponsor
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Oak Lawn, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting No phase listed Observational

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

NCT06780241
View directory record Official record
Conditions
Aortic Regurgitation, Mitral Regurgitation, Aortic Stenosis
Interventions
CMR, Quality of Life Questionnaire
Diagnostic Test · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

NCT02461602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Use of Electronic Personal Health Records to Improve Medication Adherence

NCT03018197
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Medication Education
Other
Lead sponsor
Parkview Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated No phase listed Observational

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

NCT03935178
View directory record Official record
Conditions
Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions
Measuring Right Ventricular Size and Function
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT02928497
View directory record Official record
Conditions
Stroke
Interventions
WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

NCT03834155
View directory record Official record
Conditions
Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease, Valvular Disease, Chronic Stable Angina, Chronic Stable Heart Failure
Interventions
Hospital-based CR + Movn Application, Choice of Hospital or home-based CR + Movn Application, Hospital-based CR + Movn Application + Nudge, Choice of Hospital or home-based CR + Movn Application + Nudge
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients

NCT00417664
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Propofol, Midazolam
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational Results available

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
25,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

NCT00359489
View directory record Official record
Conditions
Heart Valve Diseases
Interventions
cardiac echosonography
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting No phase listed Observational

A Study Of Clinical Implications Of Pulmonary Vascular Disease In Valvular Heart Disease

NCT07483203
View directory record Official record
Conditions
Pulmonary Vascular Disease, Valvular Heart Disease
Interventions
Echocardiogram
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Results available

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

NCT03795298
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX Implant, Market-approved OAC
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

NCT01896297
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pradaxa, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Hot Springs, Arkansas • Fremont, California • Moreno Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Results available

Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

NCT00721136
View directory record Official record
Conditions
Bradycardia, Tachycardia, Atrial Fibrillation, Valvular Heart Disease
Interventions
continue warfarin through the procedure, Hold warfarin, Warfarin held with heparin transition.
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

NCT04956978
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Support Tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Withdrawn No phase listed Observational

Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography

NCT00774657
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Results available

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

NCT02702271
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 21, 2026, 11:24 AM EDT
Not yet recruiting Not applicable Interventional

NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial

NCT06511505
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Diseases, Arrhythmia, Valvular Disease
Interventions
TEMPUS AI-enabled ECG-based Screening Tool
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jul 21, 2026, 11:24 AM EDT